登录 注册 会员服务 联系我们

Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients

  • Published:2020-05-23 Issue:7 Volume:111 Page:2526-2535
  • ISSN:1347-9032
  • Container-title:Cancer Science
  • language:en
  • Short-container-title:Cancer Sci

Author:

Yamazaki Kiyotaka1,Inagaki Naohito1,Moldaver Daniel2,Viana Ricardo3,Kimura Shinya4ORCID

Affiliation:

1. Novartis Pharma K.K. Tokyo Japan

2. EVERSANA Burlington ON Canada

3. Novartis Pharmaceuticals East Hanover NJ USA

4. Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine Saga University Saga Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Reference45 articles.

1. Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib;Emole J;Biologics,2016

2. Tyrosine kinase inhibitors in Ph+ chronic myeloid leukemia therapy: a review;Shah K;Asian Pac J Cancer Prev,2016

3. Differences in incidence and trends of haematological malignancies in J apan and the U nited S tates

4. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned

5. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines.
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3